# Pemetrexed

## Alimta inj 100mg

| 藥物代碼 | IALI1 |
| :--- | :--- |
| 適應症 | In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. |
| 副作用 | Bone marrow depression with neutropenia, leukopenia, anemia & thrombocytopenia; fatigue; fever; GI toxicity with nausea & vomiting, constipation, anorexia, anorexia, stomatitis/pharyngitis, diarrhea; dyspnea; chest pain; infection; rash/desquamation. |
| 禁忌 | Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications \(not in the US labeling\): Concomitant yellow fever vaccine. |
| 藥物保存方式 | 室溫 |
| 用法用量 | 500 mg/m2 by IV infusion over 10 mins on Day 1 of each 21-day cycle. In malignant mesothelioma, cisplatin \(75 mg/m2\) is given 30 mins after the end of pemetrexed infusion. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Hold Breast Feeding 暫停哺乳 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## ALIMTA inj 500mg

| 藥物代碼 | IALI5 |
| :--- | :--- |
| 適應症 | In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. |
| 副作用 | Bone marrow depression with neutropenia, leukopenia, anemia & thrombocytopenia; fatigue; fever; GI toxicity with nausea & vomiting, constipation, anorexia, anorexia, stomatitis/pharyngitis, diarrhea; dyspnea; chest pain; infection; rash/desquamation.Dermatologic: Itching, Itching \(1% to 7% \), Peeling of skinGastrointestinal: Constipation \(1% to 21% \), Diarrhea \(5% to 17% \), Loss of appetite \(19% to 27% \), Nausea \(19% to 82% \), Pharyngitis, Stomatitis, Vomiting \(9% to 57% \)Hematologic: Anemia, All Grades \(15% to 33% \), Leukopenia, All Grades \(6% to 53% \), Neutropenia, All Grades \(6% to 56% \), Thrombocytopenia, All Grades \(1% to 23% \)Other: Fatigue \(25% to 48% \) |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | 500 mg/m2 by IV infusion over 10 mins on Day 1 of each 21-day cycle. In malignant mesothelioma, cisplatin \(75 mg/m2\) is given 30 mins after the end of pemetrexed infusion. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | N/A |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 本藥品不可與含有鈣離子的溶液混合。 3. 監測CBC、肝腎功能。 4. 建議監測homocysteine血中濃度。 |

